:S 100 pg/ml). Both tests were negative to atracurium. Five years ago the patient also reported a large local urticaria after topical use of lidocaine (EMLA® anesthetic disc, AstraZeneca, USA). After obtaining the patient's consent, the diagnostic approach was carried out. Skin tests were performed with commercial LA drugs.
Positive skin-prick test results with fullstrength drug were obtained for lidocaine (AstraZeneca) with a wheal diameter of 5 x 4 mm, bupivacaine (AstraZeneca) with 6 x 4 mm and mepivacaine (Laboratorios lnibsa, Portugal) with 4 x 3 mm. Skin-prick test for ropivacaine (AstraZeneca) was negative, but the intradermal (TD) test with I : 100 dilution was positive (12 x 10 mm). Then, we performed skin tests (prick and TD testing) with procaine (Labesfal, Portugal), the LA belonging to the ester group, which were negative. On the next day, the patient was admitted to an intensive care unit for challenge procedures. The subcutaneous challenge with I ml of procaine (2%) was negative, (three biopsies~forearm and thigh), with no adverse reactions. In order to ensure that the positive skin test results were relevant, we carried out placebo controlled (saline), single-blind subcutaneous challenge test with 0.1 ml of ropivacaine (0.2%, preservative-free solution), and it was strongly positive (severe systemic reaction with laryngospasm, treated with parenteric epinephrine), confirming the diagnosis of allergy to LA of the amide group. The immediate hypersensitivity reaction was proved in this case and, as far as we know, this is the first report of severe hypersensitivity to ropivacaine, a drug unique among LA because it is prepared as an isomer (the S-enantiomer of the propyl homologue of bupivacaine) rather than a racemic mixture. The therapeutic alternative was procaine, the ester anesthetic, not routinely used nowadays. In conclusion, although ropivacaine is a first-choice drug for the majority of LA allergic patients, cross-reactivity must be thought within the amide group, in patients with positive skin tests (4); in these cases, allergy evaluation must be accomplished in a reference centre in order to identify safe alternatives (3). 
